The Esperion Therapeutics Inc. (ESPR) shares are trading at lower $33.48 and the avg recommendation for the stock is Strong Buy.
To add more color to this target, the company’s high over the last year is $76.98 and the low is $24.82. Over the last 52 weeks, ESPR is down -56.51% while the S&P 500 is down -0.83%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, ESPR reported a profit of $1.81 million. Esperion Therapeutics Inc. also saw revenues increase to $1.84 million. In addition, ESPR has free cash flow of -$69.54 million as of 03-2020. The company’s EBITDA came in at -$74.41 million which compares well with its peers.
ESPR Return on Equity (ROE) is -627.40%, and its Return on Assets is -109.70%. All told, it is clear that, ESPR needs to be on your watchlist.
Find out when ESPR reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. ESPR has a short ratio of 15.67 and outstanding shares of 27.52M.
ESPR has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.77 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -9.63. Esperion Therapeutics Inc. ESPR also noted assets of $179.64 million at the end of the last quarter. Investors should also keep an eye on sector updates as ESPR has historically followed its peers on positive news.
All told, Esperion Therapeutics Inc. ESPR has strung together solid data and demonstrated underlying fundamentals. At its current valuation, ESPR represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Esperion Therapeutics Inc. ESPR is now commanding a market cap of 938.44M and a float of 27.35M. ESPR is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of ESPR stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in ESPR, either long or short, and we have not been compensated for this article.